Publication Topic

Haselkorn T, Roca A, Miller B, Jensen I, Solomon F, Sanchez-de la Rosa R, Picart JM, Nascimento A. A real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in Spain. Presented at LXXVI Reunion Annual de la Sociedad Espanola de Nurologica, 19–23 November 2024.

Kelsh M, Bylsma LC, Jiang X, Movva N, Sacks NC. To be an orphan disease or not to be: An evaluation of prevalence estimates for cancers near the orphan status threshold and implications for orphan drug planning. International Society for Pharmacoepidemiology, 40^th Annual Meeting, Berlin, Germany, August 2024.

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. The 18-effectiveness of atidarsagene autotemcel (ARSA-CEL) for the treatment of metachromatic leukodystrophy (MLD) in Spain, ISPOR Europe 2024, November 2024.

Seo S, Healey BE, McLin R, Sacks NC, Benson CJ, Citrome L. 2024. Impact of demographics and insurance coverage on schizophrenia treatment and healthcare resource utilization within an integrated healthcare system. Neuropsychiatr Dis Treat 20(Sept 26):1837–1848; doi: 10.2147/NDT.S473492. PMID: 39351585.

DiBiase JF, Scharnetzki E, Edelman E, Reed EK, Helbig P, Rueter J, Miesfeldt S, Frankenfeld CL, et al. 2024. Socioeconomic and urban-rural disparities in genome-matched treatment receipt and survival after genomic tumor testing. JNCI Cancer Spectr 8(5):pkae090; doi: 10.1093/jncics/pkae090. PMID: 39312685.

Bean K, Jones SA, Chakrapani A, Vijay S, Wu T, Church H, … Jensen I, et al. 2024. Exploring the cost-effectiveness of newborn screening for metachromatic leukodystrophy (MLD) in the UK. Int J Neonatal Screen 10(3):45; doi: 10.3390/ijns10030045.

Chew DS, Sacks NC, Emden MR, Cyr PL, Sherwood R, Pokorney SD. 2024. Catheter ablation for supraventricular tachycardia and health resource utilization and expenditures: A propensity-matched cohort study. Int J Cardiol 403(May 15):131831; doi: 10.1016/j.ijcard.2024.131831. PMID: 38331201.

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr PL, Sawyer EK, Stephen CD, et al. 2024. Burden of illness and mortality in men with adrenomyeloneuropathy: A retrospective cohort study. Orph J Rare Dis 19(1):270; doi: 10.1186/s13023-024-0326-w. PMID: 39020416.

Hernandez L, Davies S, Li C, Reddick E, Jensen I. A cost-consequence analysis of ponatinib versus imatinib in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia in the United States. Abstract EE165, ISPOR 2024 (Top 5% Finalist).

Minshall ME, Liu Y, Wagner A, Jensen IS, Corman S. The cost for of chronic lung allograft dysfunction (CLAD) in lung transplant (LTX) recipients by stage 1-4: A claims database analysis. Abstract EE70, ISPOR 2024.